Open AccessThis article is
- freely available
Developing Vaccines to Combat Pandemic Influenza
Division of Virology, National Institute for Biological Standards and Control, Health Protection Agency, Blanche Lane, South Mimms, Potters Bar, EN6 3QG, UK
* Author to whom correspondence should be addressed.
Received: 25 November 2009; in revised form: 28 January 2010 / Accepted: 29 January 2010 / Published: 2 February 2010
Abstract: Influenza vaccine manufacturers require antigenically relevant vaccine viruses that have good manufacturing properties and are safe to use. In developing pandemic vaccine viruses, reverse genetics has been employed as a rational approach that can also be used effectively to attenuate the highly virulent H5N1 virus and at the same time place the H5 HA and N1 NA on a background of PR8, a virus that has been used over many decades to provide high yielding vaccine viruses. Reverse genetics has also been used successfully alongside classical reassorting techniques in the development of (swine flu) pandemic A(H1N1)v vaccine viruses.
Keywords: pandemic influenza vaccines; reverse genetics; H5N1 virus; H1N1v virus
Citations to this Article
Cite This Article
MDPI and ACS Style
Robertson, J.S.; Engelhardt, O.G. Developing Vaccines to Combat Pandemic Influenza. Viruses 2010, 2, 532-546.
Robertson JS, Engelhardt OG. Developing Vaccines to Combat Pandemic Influenza. Viruses. 2010; 2(2):532-546.
Robertson, James S.; Engelhardt, Othmar G. 2010. "Developing Vaccines to Combat Pandemic Influenza." Viruses 2, no. 2: 532-546.